<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mildly thrombocytopenic patients with relapsed or refractory low-grade non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) have an increased risk of chemotherapy-induced <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> following treatment </plain></SENT>
<SENT sid="1" pm="."><plain>The safety and efficacy of radioimmunotherapy with a reduced dose of (90)Y ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]; maximum 32 mCi [1.2 GBq]) was evaluated in 30 patients with mild <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (100-149 x 10(9) platelets/L) who had advanced, relapsed or refractory, low-grade, follicular, or transformed B-cell NHL </plain></SENT>
<SENT sid="2" pm="."><plain>The ibritumomab tiuxetan regimen included an infusion of rituximab (250 mg/m(2)) and injection of (111)In ibritumomab tiuxetan (5 mCi [185 MBq]) for dosimetry evaluation, followed 1 week later with rituximab (250 mg/m(2)) and (90)Y ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients (median age, 61 years; 90% stage III/IV at study entry; 83% follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>; and 67% with bone marrow involvement) had a median of 2 prior therapy regimens (range, 1-9) </plain></SENT>
<SENT sid="4" pm="."><plain>Estimated radiation-absorbed doses were well below the study-defined maximum allowable for <z:hpo ids='HP_0000001'>all</z:hpo> 30 patients </plain></SENT>
<SENT sid="5" pm="."><plain>With the use of the International Workshop criteria for NHL response assessment, the overall response rate was 83% (37% complete response, 6.7% complete response unconfirmed, and 40% partial response) </plain></SENT>
<SENT sid="6" pm="."><plain>Kaplan-Meier estimated median time to progression (<z:chebi fb="1" ids="18284">TTP</z:chebi>) was 9.4 months (range, 1.7-24.6) </plain></SENT>
<SENT sid="7" pm="."><plain>In responders, Kaplan-Meier estimated median <z:chebi fb="1" ids="18284">TTP</z:chebi> was 12.6 months (range, 4.9-24.6), with 35% of data censored </plain></SENT>
<SENT sid="8" pm="."><plain>Toxicity was primarily hematologic, transient, and reversible </plain></SENT>
<SENT sid="9" pm="."><plain>The incidence of grade 4 <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, and <z:hpo ids='HP_0001903'>anemia</z:hpo> was 33%, 13%, and 3%, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>Reduced-dose ibritumomab tiuxetan is safe and well tolerated and has significant clinical activity in this patient population </plain></SENT>
</text></document>